Following the closing of the merger, BioTime owns approx. 84% of the combined company, and prior Asterias stockholders own approx. 16%.
BioTime is now advancing three clinical stage product candidates for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer.
Subscribe for full text news in your inbox